People: Ista Pharmaceuticals Inc (ISTA.O)

ISTA.O on Consolidated Issue listed on NASDAQ Global Market

3.76USD
9 Feb 2010
Price Change (% chg)

$0.17 (+4.74%)
Prev Close
$3.76
Open
--
Day's High
$3.89
Day's Low
$3.69
Volume
302,772
Avg. Vol
154,074
52-wk High
$6.83
52-wk Low
$1.01

view people for:

Summary

Name Age Since Current Position
Williams, Richard 65 2004 Chairman of the Board
Anido, Vicente 56 2001 President, Chief Executive Officer, Director
Silvernail, Lauren 50 2003 Chief Financial Officer, Vice President - Corporate Development, Chief Accounting Officer
McMullin, Kirk 55 2002 Vice President - Operations
Mitro, Thomas 51 2002 Vice President - Sales and Marketing
McGinley, Kathleen 59 2003 Vice President - Human Resources and Corporate Services
Garrett, Marvin 58 1999 Vice President - Regulatory Affairs, Quality & Compliance
McNamara, Timothy 53 2006 Vice President - Clinical Research and Medical Affairs
McGraw, Benjamin 59 2002 Director
Roe, Wayne 58 2002 Director
LaPorte, Kathleen 47 2002 Director
Hutt, Peter 74 2002 Director
Mitchell, Dean 53 2004 Director
Perlman, Andrew 61 2006 Director
» Insider Trading

Biographies

Name Description
Williams, Richard Richard C. Williams has served on the Board of Directors since December 2002 and as Chairman of the Board of Directors of ISTA Pharmaceuticals, Inc. since July 2004. Since 1989, Mr. Williams has served as the founder and President of Conner-Thoele Limited, a consulting and financial advisory firm specializing in the healthcare industry and pharmaceutical segment. From 2000 to April 2001, Mr. Williams also served as Vice Chairman-Strategic Planning and director of King Pharmaceuticals, Inc., a public company. From 1992 to 2000, Mr. Williams served as Chairman and director of Medco Research, a then-public cardiovascular pharmaceutical development company, prior to its acquisition by King Pharmaceuticals in 2000. From 1997 to 1999, Mr. Williams was Co-Chairman and a director of Vysis, Inc., a then-public genetic biopharmaceutical company. Prior to founding Conner-Thoele Limited, Mr. Williams held various operational and financial management officer positions with Abbott Laboratories, a public company, and Erbamont, N.V., Field Enterprises, Inc., and American Hospital Supply Corporation, all of which are private companies. Mr. Williams is also a director, Chairman and interim Chief Executive Officer of Adamis Pharmaceuticals Corporation, a public specialty biopharmaceutical company. Mr. Williams received a B.A. degree from DePauw University and an M.B.A. from the Wharton School of Finance.
Anido, Vicente Vicente Anido, Jr., Ph.D. has served as President and Chief Executive Officer and on the Board of Directors of ISTA Pharmaceuticals, Inc. since December 2001. From June 2000 to September 2001, Dr. Anido was general partner for Windamere Venture Partners. From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a private biotechnology company. From 1993 to 1996, he served as President of the Americas Region of Allergan, Inc., a public company. Dr. Anido received a Ph.D. in Pharmacy Administration from the University of Missouri.
Silvernail, Lauren Lauren P. Silvernail has served as Chief Financial Officer, Chief Accounting Officer and Vice President, Corporate Development of ISTA Pharmaceuticals, Inc. since March 2003. From 1995 to March 2003, Mrs. Silvernail served in various operating and corporate development positions for Allergan, Inc., a public company, most recently serving as Vice President, Business Development. From 1989 to 1994, she was a general partner at Glenwood Ventures and served as a director and operating manager for several portfolio companies. Mrs. Silvernail received a M.B.A. from the University of California, Los Angeles.
McMullin, Kirk Kirk McMullin has served as Vice President, Operations of ISTA Pharmaceuticals, Inc. since August 2002. From 1995 to 2002, Mr. McMullin was Vice President, Worldwide Manufacturing Support for Allergan. Mr. McMullin received a B.A. from Humboldt State University.
Mitro, Thomas Thomas A. Mitro has served as Vice President, Sales & Marketing of ISTA Pharmaceuticals, Inc. since July 2002. From 1980 to 2002, Mr. Mitro held several positions at Allergan, including Vice President, Skin Care, Vice President, Business Development and Vice President, e-Business. Mr. Mitro received a B.S. degree from Miami University.
McGinley, Kathleen Kathleen McGinley has served as Vice President, Human Resources and Corporate Services of ISTA Pharmaceuticals, Inc. since November 2003. From January 2003 to November 2003, Ms. McGinley served as a consultant to ISTA. From May 2000 to January 2003, Ms. McGinley served as Director and Vice President, Human Resources for Littlefeet, Inc. From December 1999 to May 2000 she served as Director of Human Resources for Combi-Chem/Dupont Pharmaceuticals in San Diego, CA. Ms. McGinley received a M.S. from the University of Tennessee, Knoxville.
Garrett, Marvin Marvin J. Garrett has served as Vice President, Regulatory Affairs, Quality & Compliance of ISTA Pharmaceuticals, Inc. since June 1999. From May 1994 to June 1999, Mr. Garrett was Vice President, Regulatory Affairs and Clinical Research for Xoma, Ltd., a biotechnology company. From 1990 to 1994, he was President and General Manager of Coopervision Pharmaceutical, a division of the Cooper Companies, Inc. Prior to joining Coopervision, Mr. Garrett was Vice President of Regulatory Affairs, Clinical Research and Quality for Iolab Pharmaceuticals, a Johnson & Johnson Company, and also Director of Regulatory Affairs for Allergan. Mr. Garrett received a B.S. in Microbiology from California State University, Long Beach.
McNamara, Timothy Timothy R. McNamara, Pharm.D. has served as Vice President, Clinical Research and Medical Affairs of ISTA Pharmaceuticals, Inc. since November 2006, and previously served as Director, Medical Affairs, from November 2004 to November 2006. Dr. McNamara was Director, Medical Affairs at Amgen Inc., a public company, from June 2001 to July 2004. Prior to that, Dr. McNamara was at Bristol-Myers Squibb, a public company, from June 1989 to January 1998, where he last served as Director, Advance Health Care Services in the Department of Medical Affairs, and served as Senior Director of Medical Affairs for Searle, a private company, from February 1998 to May, 2000, and was Chief Executive Officer of PRN Inc., a private contract research organization, from June 2000 to June 2001. Dr. McNamara also held the position of Associate Professor at St. Louis College of Pharmacy and Samford University, and Clinical Pharmacist for the Program on Aging at Jewish Hospital and Washington University, School of Medicine, St Louis. Dr. McNamara received his B.S. in Pharmacy in 1979, and his Pharm.D. in 1981 from University of Missouri, Kansas City.
McGraw, Benjamin Benjamin F. McGraw, III, Pharm.D. has served on the Board of Directors of ISTA Pharmaceuticals since April 2000, except for the period from November 2002 to December 2002. Dr. McGraw is the managing member of Long Shadows Asset Management, LLC, an investment advisory company. Prior to this, Dr. McGraw was President and Chief Executive Officer since 1994, director since 1996, and Treasurer since 2006, of Valentis, Inc., a biotechnology company, until Valentis, Inc. was acquired by Urigen Pharmaceuticals, Inc. in July 2007. Prior to this, Dr. McGraw was Corporate Vice President for Corporate Development of Allergan, Inc., a public specialty pharmaceutical company focusing on ophthalmology, dermatology and neuromuscular indications. Before that, he was an equity analyst and a fund manager at Carerra Capital Management. Prior to this, he was Vice-President, Development for Marion Laboratories and Marion, Merrell Dow, both of which are private companies. Dr. McGraw is a director and Chairman of TRF Pharma, Inc., a private biotechnology company, and is also a director of Urigen Pharmaceuticals, Inc., a public company. Dr. McGraw received B.S. and Doctor of Pharmacy degrees from the University of Tennessee Center for the Health Sciences, where he also completed a clinical practice residency.
Roe, Wayne Wayne I. Roe has served on Board of Directors of ISTA Pharmaceuticals, Inc. since June 1998, except for the period from November 2002 to December 2002. Mr. Roe was Senior Vice President for United Therapeutics Corporation, a public biotechnology company, from November 1999 to November 2000. From November 1988 to March 1999, Mr. Roe founded and served in various management positions at Covance Health Economics and Outcome Services, a consulting firm for life sciences companies, last serving as Chairman of the board of directors. Mr. Roe has been a general partner in DFJ IoCube Ventures, Inc., a medical device-focused venture capital firm, since 2008. Mr. Roe is also currently a director of Celera Genomics Inc., a private biotechnology company focused on genetic diagnostic testing. Mr. Roe received an M.A. in Political Economy from the State University of New York and an M.A. in Economics from the University of Maryland.
LaPorte, Kathleen Kathleen D. LaPorte has served on Board of Directors of ISTA Pharmaceuticals, Inc. since November 2002. Ms. LaPorte is a Managing Director of New Leaf Venture Partners, LLC located in Menlo Park, California. Previously, Ms. LaPorte was a General Partner of the Healthcare Technology Group of the Sprout Group located in Menlo Park, California, which she joined in 1993 and became a General Partner in 1994. Between 1987 and 1993, Ms. LaPorte was a principal at Asset Management Company, a venture capital firm focused on early-stage investments. Previously, Ms. LaPorte was a financial analyst with The First Boston Corporation. Ms. LaPorte is a member of the board of directors of Affymax, Inc. and Transcept Pharmaceuticals, Inc., both of which are public companies. Ms. LaPorte received a B.S. from Yale University and a M.B.A. from Stanford University Graduate School of Business.
Hutt, Peter Peter Barton Hutt has served on the Board of Directors of ISTA Pharmaceuticals since November 2002. Mr. Hutt is senior counsel specializing in food and drug law in the Washington, D.C. law firm of Covington & Burling. From time to time, Covington & Burling provides legal services to the company. Mr. Hutt joined Covington & Burling in 1960 and was named partner in 1968, leaving from 1971 to 1975 to serve as Chief Counsel for the U.S. Food and Drug Administration and returning to Covington & Burling in September 1975. Mr. Hutt is the co-author of the casebook used to teach Food and Drug Law throughout the country and teaches a full course on the subject annually at Harvard Law School. Mr. Hutt is a member of the board of directors of Momenta Pharmaceuticals, Inc. and Xoma Ltd., both of which are public companies, and Celera Corporation, a private company. Mr. Hutt received a B.A. from Yale University and a LL.B. from Harvard University. In addition, Mr. Hutt received a Master of Laws degree in Food and Drug Law from New York University Law School.
Mitchell, Dean Dean J. Mitchell was appointed to Board of Directors of ISTA Pharmaceuticals, Inc. in July 2004. In July 2006, Mr. Mitchell assumed the role of President and Chief Executive Officer of Alpharma Inc., a public global specialty pharmaceutical company, and was also appointed a member of its board of directors. Alpharma Inc. was acquired by King Pharmaceuticals, Inc. in December 2008, and Mr. Mitchell ceased to be a director of Alpharma Inc. on December 29, 2008. Prior to Alpharma Inc., he was President and Chief Executive Officer of Guilford Pharmaceuticals Inc., a public company, from December 2004 until its acquisition by MGI Pharma Inc., a public company, in October 2005 and was a non-executive director of MGI Pharma Inc. until its acquisition by Eisai Co., Ltd. in January 2008. Mr. Mitchell was at Bristol-Myers Squibb, a public company, from 2001 until 2004 in several roles including President, International, President U.S. Primary Care and Vice President, Strategy. He also spent 15 years at Glaxo SmithKline, a public company, and its predecessor companies, most recently as Senior Vice President, Clinical Development and Product Strategy from 1999 to 2001, and prior to that as Vice President and General Manager, Specialty Divisions, Strategic Planning and Business Development, from 1995 to 1999. He received his MBA degree from City University Business School, in London, UK, and his B.Sc. degree in Biology from Coventry University, UK.
Perlman, Andrew Andrew J. Perlman, M.D., Ph.D. was appointed to Board of Directors of ISTA Pharmaceuticals, Inc. in April 2006. Dr. Perlman is the co-founder, and has served since October 2004 as the Chief Executive Officer, of Innate Immune, Inc., a private company engaged in the discovery and development of therapeutics for asthma and autoimmune diseases. Dr. Perlman served in various senior management positions, culminating as Executive Vice President, at Tularik, Inc., a public biotechnology company, from 1993 through October 2004, except from February to October 2002, when he served as the Chief Executive Officer and a member of the board of directors of Affymax, Inc., a private biopharmaceutical company. While at Tularik, Inc., Dr. Perlman’s principal responsibilities were in the areas of clinical research and business development in which he provided medical input and strategy for all Tularik, Inc.’s clinical projects, and played an active role in Tularik Inc.’s financing activities and in its merger with Amgen in 2004. Prior to 1993, Dr. Perlman was a Senior Director of Clinical Research at Genentech, Inc., a public company, and served as a faculty member in the Department of Medicine at Stanford University. Dr. Perlman presently is a member of the board of directors of Innate Immune, Inc. Dr. Perlman received his M.D. and his Ph.D. in Physiology from New York University.

Basic Compensation

Name Fiscal Year Total
Williams, Richard --
Anido, Vicente 1,246,430
Silvernail, Lauren 560,924
McMullin, Kirk 394,545
Mitro, Thomas 559,001
McGinley, Kathleen --
Garrett, Marvin 546,509
McNamara, Timothy 510,933
McGraw, Benjamin --
Roe, Wayne --
LaPorte, Kathleen --
Hutt, Peter --
Mitchell, Dean --
Perlman, Andrew --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Williams, Richard 0 0
Anido, Vicente 595,000 1,707,655
Silvernail, Lauren 165,000 158,400
McMullin, Kirk 0 0
Mitro, Thomas 164,000 470,680
McGinley, Kathleen 0 0
Garrett, Marvin 208,795 750,966
McNamara, Timothy 0 0
McGraw, Benjamin 0 0
Roe, Wayne 0 0
LaPorte, Kathleen 0 0
Hutt, Peter 0 0
Mitchell, Dean 0 0
Perlman, Andrew 0 0

Insider Trading

Name Shares Traded Price
SILVERNAIL LAUREN P 989 $3.60
MCGINLEY KATHLEEN 879 $3.60
ANIDO VICENTE JR 3,995 $3.60
MCMULLIN KIRK 879 $3.60
MCGINLEY KATHLEEN 8,000 $0.00
MCNAMARA TIMOTHY 8,000 $0.00
SILVERNAIL LAUREN P 769 $3.63
MCGINLEY KATHLEEN 692 $3.63
MITRO THOMAS A 16,700 $0.00
GARRETT MARVIN J 8,000 $0.00
MCNAMARA TIMOTHY 604 $3.63
ANIDO VICENTE JR 36,350 $0.00
MCMULLIN KIRK 8,000 $0.00
MITRO THOMAS A 879 $3.63
SILVERNAIL LAUREN P 9,000 $0.00
GARRETT MARVIN J 769 $3.63
ANIDO VICENTE JR 2,286 $3.63
MCMULLIN KIRK 769 $3.63
ROE WAYNE I 32,500 $3.49
MITRO THOMAS A 1,900 $3.30
ANIDO VICENTE JR 4,000 $0.00
MITRO THOMAS A 4,000 $2.00
ANIDO VICENTE JR 10,000 $1.97
ANIDO VICENTE JR 17,500 $1.99
ANIDO VICENTE JR 3,444 $1.97
» Full list on Insider Trading
view people for: